<?xml version="1.0" encoding="UTF-8"?>
<p id="para230">Now several clinical trials of hydroxychloroquine are in the works, including one that began on 24 March in New York, in which the drug will be evaluated in combination with azithromycin. Should its efficacy be proven, the low cost and ready availability of hydroxychloroquine should make it easy to mass produce for widespread use. Yet some are wary of heaping too much hope onto this one solution – Trump's enthusiasm notwithstanding. At this point, the hype around hydroxychloroquine says more about our desperation than its genuine promise, says 
 <ext-link ext-link-type="uri" xlink:href="https://www.urmc.rochester.edu/people/20864972-harold-c-smith" id="interrefs190" xmlns:xlink="http://www.w3.org/1999/xlink">Harold Smith</ext-link>, a molecular biologist at the University of Rochester in New York and founder of a company also developing an antiviral treatment against the new coronavirus with NIAID funding. “Nations have been brought down by this itty-bitty virus, and we have nothing,” he says.
</p>
